Biohaven (BHVN) Change in Account Payables (2021 - 2026)
Biohaven (BHVN) reported Change in Account Payables of -$1.2 million for Q1 2026, down 1441.76% on a YoY basis from $91000.0 in Q1 2025, and up 79.12% sequentially from -$5.8 million in Q4 2025.
Biohaven (BHVN) Change in Account Payables (2021 - 2026) Analysis & Trends
Biohaven (BHVN) has 6 years of Change in Account Payables data on file, last reported at -$1.2 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 1441.76% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$7.7 million (up 57.85% YoY), and the FY2025 full-year result was -$6.4 million, down 999.44% from the prior year.
- Change in Account Payables climbed to -$1.2 million in Q1 2026, from -$5.8 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $19.1 million in Q1 2024 to a low of -$19.1 million in Q2 2024.
- A 5-year average of $229705.9 and a median of -$325000.0 in 2022 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables jumped 408.02% in 2024 and plunged 1441.76% in 2026, its largest moves.
- Tracing BHVN's Change in Account Payables over 5 years: stood at $6.0 million in 2022, then advanced by 1.51% to $6.1 million in 2023, then slumped by 128.29% to -$1.7 million in 2024, then sank by 240.99% to -$5.8 million in 2025, then soared by 79.12% to -$1.2 million in 2026.
- Business Quant data shows BHVN's Change in Account Payables at -$1.2 million in Q1 2026, -$5.8 million in Q4 2025, and -$2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.04 Bn | 467.25 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 122.28 Bn | 115.03 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.16 Bn | 50.98 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.56 Bn | 34.55 Bn | 959.66 Mn | - |
| 10 | Biohaven | 2.16 Bn | 1.81 Bn | - | -1.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.22 Mn |
| Mar 31, 2026 | -1.22 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | 1.51 Mn |
| Jun 30, 2025 | 1.51 Mn |
| Mar 31, 2025 | 91,000.00 |
| Mar 31, 2025 | 91,000.00 |
| Dec 31, 2024 | -1.72 Mn |
| Dec 31, 2024 | -1.72 Mn |
| Sep 30, 2024 | 2.49 Mn |
| Sep 30, 2024 | 2.49 Mn |
| Jun 30, 2024 | -19.13 Mn |
| Jun 30, 2024 | -19.13 Mn |
| Mar 31, 2024 | 19.07 Mn |
| Mar 31, 2024 | 19.07 Mn |
| Dec 31, 2023 | 6.06 Mn |
| Dec 31, 2023 | 6.06 Mn |